Michael Koslowski
Michael Koslowski
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Dysfunction of ventral striatal reward prediction in schizophrenia
G Juckel, F Schlagenhauf, M Koslowski, T Wüstenberg, A Villringer, ...
Neuroimage 29 (2), 409-416, 2006
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics
G Juckel, F Schlagenhauf, M Koslowski, D Filonov, T Wüstenberg, ...
Psychopharmacology 187, 222-228, 2006
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine
F Schlagenhauf, G Juckel, M Koslowski, T Kahnt, B Knutson, T Dembler, ...
Psychopharmacology 196, 673-684, 2008
Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance
M Wolff, R Evens, LJ Mertens, M Koslowski, F Betzler, G Gründer, ...
Frontiers in psychiatry 11, 501786, 2020
Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia
M Ballmaier, F Schlagenhauf, AW Toga, J Gallinat, M Koslowski, M Zoli, ...
Schizophrenia research 106 (2-3), 140-147, 2008
Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia
G Juckel, E Friedel, M Koslowski, H Witthaus, S Özgürdal, Y Gudlowski, ...
Neuropsychobiology 66 (1), 50-56, 2012
Chorea in systemic lupus erythematosus
JF Baizabal-Carvallo, M Alonso-Juarez, M Koslowski
JCR: Journal of Clinical Rheumatology 17 (2), 69-72, 2011
Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory
F Schlagenhauf, T Wüstenberg, K Schmack, M Dinges, J Wrase, ...
European Neuropsychopharmacology 18 (8), 589-599, 2008
Novel treatment approaches for substance use disorders: therapeutic use of psychedelics and the role of psychotherapy
M Koslowski, MW Johnson, G Gründer, F Betzler
Current Addiction Reports, 1-11, 2021
Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)–Rationale and study design
LJ Mertens, M Koslowski, F Betzler, R Evens, M Gilles, A Jungaberle, ...
Neuroscience Applied 1, 100104, 2022
Using routine MRI data of depressed patients to predict individual responses to electroconvulsive therapy
M Gärtner, E Ghisu, AL Herrera-Melendez, M Koslowski, S Aust, P Asbach, ...
Experimental neurology 335, 113505, 2021
Cannabis use, use motives and cannabis use disorder among Berlin college students
H Naegele, F Betzler, L Viohl, M Koslowski, F Ernst, MB Petzold
Journal of Drug Issues 52 (4), 568-584, 2022
Converging theories on dreaming: Between Freud, predictive processing, and psychedelic research
M Koslowski, MP de Haas, T Fischmann
Frontiers in human neuroscience 17, 1080177, 2023
Le rôle de la psychothérapie dans la thérapie assistée par les psychédéliques
M Koslowski, C Dauré, M Ljuslin
L’Information psychiatrique 99 (10), 703-709, 2023
Ventral striatum activation by typical versus atypical neuroleptics in a fMRI paradigm with monetary incentive stimuli
G Juckel, F Schlagenhauf, M Koslowski, D Filonow, B Knutson, J Wrase, ...
Pharmacopsychiatry 38 (05), A109, 2005
Therapie mit Psychedelika
M Koslowski, A Ströhle
Die Psychotherapie 69 (2), 83-84, 2024
Ethische Aspekte der Therapie mit Psychedelika
D Repantis, M Koslowski, SB Fink
Die Psychotherapie, 1-7, 2024
Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen
L Becher, F Nanni, M Koslowski
Nervenheilkunde 42 (07/08), 450-458, 2023
OH Turnbull, DF Mosri, SA Mota-Rolim, M Koslowski, M Koslowski, ...
Frontiers in psychodynamic neuroscience, 231, 2023
P. 0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)–study design, rationale and current status
LJ Mertens, M Koslowski, F Betzler, R Evens, M Gilles, A Jungaberle, ...
European Neuropsychopharmacology 53, S306, 2021
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20